SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the "Drug Clinical Trial Approval Notice" approved...
The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments